Scinai Immunotherapeutics (SCNI) EBITDA Margin (2024)

Scinai Immunotherapeutics' (SCNI) quarterly EBITDA Margin came in at 1098.54% in Q4 2024, up 23.74% quarter-over-quarter from 1440.48% in Q3 2024.

Scinai Immunotherapeutics (SCNI) EBITDA Margin (2024) Analysis & Trends

Scinai Immunotherapeutics has disclosed EBITDA Margin across 1 years of filings, most recently posting 1098.54% for Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -6.43%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 38.10%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Scinai Immunotherapeutics 3.02 Bn 988.23 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -1,098.54%
Sep 30, 2024 -1,440.48%